Introduction
============

Obesity, defined as a body mass index (BMI)⩾30, is a major global public health concern, with over 500 million people worldwide classified as overweight or obese.^[@bib1]^ As well as being linked to metabolic disorders,^[@bib2],\ [@bib3],\ [@bib4]^ the maximum muscle strength produced by obese individuals is significantly less than that generated by non-obese people when normalised to body mass,^[@bib5]^ limb lean mass,^[@bib6]^ or to the muscle physiological cross-sectional area (PCSA).^[@bib7]^ This could lead to major functional limitations for daily living activities, such as climbing/descending stairs, rising from a chair, recovering from a trip, etc., which in turn could lead to hospitalisation and reduced quality of life.

There are a number of reasons why muscle quality (defined here as muscle specific force, i.e., the maximum force per unit PCSA) might be lower in obese vs non-obese people. Fat infiltration within the skeletal muscle reduces the contractile component of the total muscle volume,^[@bib8]^ thereby lowering the intrinsic strength of the whole muscle.^[@bib9]^ Furthermore, intramuscular lipid acts as a chemoattractant for macrophages,^[@bib10]^ which produce pro-inflammatory cytokines,^[@bib11]^ such as tumour necrosis factor-alpha (TNF-α)^[@bib12]^ and interleukin-6 (IL-6).^[@bib13]^ This chronic immune response is characterised by elevated concentrations of these pro-inflammatory cytokines in the blood resulting in chronic low-grade systemic inflammation, which has been observed in young^[@bib12],\ [@bib14]^ and older^[@bib15]^ obese people. To compound this problem, both adipocytes^[@bib16]^ and macrophages^[@bib11]^ secrete pro-inflammatory cytokines, and it has been suggested that fat accounts for approximately 30% of serum IL-6 levels in humans.^[@bib17]^ Thus, a chronically inflamed environment is created within and around the muscle containing substantial intramuscular fat. Crucially, as well as acting as chemoattractants, these cytokines are directly involved in the breakdown of muscle protein.^[@bib18]^ This would interfere with the accretion of contractile material caused by the chronic low-intensity overloading of the muscle,^[@bib19]^ thus reducing muscle specific force. However, it is unclear to what extent chronic inflammation is responsible for the reduction in muscle quality and muscle function in obese individuals.

As well as the increase in obesity incidence, we are living for longer. This is particularly relevant, as ageing is associated with a decrease in muscle activation capacity,^[@bib20]^ loss of muscle size,^[@bib21]^ a decrease in the fascicle pennation angle,^[@bib22]^ i.e., the angle at which the fascicles insert into the lower aponeurosis \[the smaller the muscle fibre CSA, the smaller the pennation angle^[@bib23]^\], and reduced muscle strength, both at the whole muscle and fascicle levels.^[@bib21]^ Collectively, these physiological changes in muscle properties with age lead to senile sarcopaenia, which is thought to be a major factor underlying the incidence of falls and reduced quality of life in older people.^[@bib24]^ Furthermore, ageing is associated with increased intramuscular fat,^[@bib25],\ [@bib26]^ which is likely a major cause of chronically elevated levels of pro-inflammatory circulating cytokines^[@bib27],\ [@bib28]^ and lower muscle specific force^[@bib21]^ in older vs younger adults. Furthermore, central inflammation, i.e., elevated pro-inflammatory cytokines in the hippocampus and hypothalamus, leads to neuroinflammation,^[@bib29]^ which might help explain the lower neuromuscular activation and absolute strength commonly observed in older vs younger individuals.^[@bib6],\ [@bib20],\ [@bib21],\ [@bib30]^ Moreover, as a high fat diet can elevate pro-inflammatory cytokine expression and activate the pro-inflammatory transcription factor nuclear factor-*κ*B (NF-*κ*B) in the hypothalamus,^[@bib31]^ it is feasible that a higher fat diet in both young and older obese individuals could have reduced ability to activate their muscles compared to leaner persons due to neuroinflammation.

Although both obesity and ageing can lead to chronic low grade systemic inflammation, it is not known if systemic inflammation in obese older adults signifies a cumulative negative impact of both ageing and obesity on skeletal muscle properties. Therefore, the aim of this study was to determine whether circulating pro-inflammatory cytokines, elevated with increased fat mass^[@bib12],\ [@bib32],\ [@bib33]^ and ageing,^[@bib27],\ [@bib28],\ [@bib34]^ could explain the different effects of obesity on skeletal muscle size, architecture and strength between young and older adults. We hypothesised that pro-inflammatory cytokines would be associated with lower muscle size and strength in both young obese and older individuals. Further, we hypothesised that circulating pro-inflammatory cytokine concentration would be inversely correlated with neuromuscular activation and strength in older and obese people.

Subjects and Methods
====================

Subjects
--------

One hundred and forty-two healthy, untrained men and women gave their written informed consent to participate in this study, which complied with the Declaration of Helsinki^[@bib35]^ and was approved by the local ethics committee of Manchester Metropolitan University. Participants were categorised according to total body fat percentage (normal: \<40% high: ⩾40% for females,^[@bib7],\ [@bib36],\ [@bib37]^ and normal: \<28% high: ⩾28% for males^[@bib36]^) and age (young: 18--49 yrs; older: 50--80 yrs), and their physical characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Within the total cohort, there were 75 young (56 women, 22 men) and 67 older (48 women, 19 men) participants ([Table 1](#tbl1){ref-type="table"}). Of the younger group, 35 women and 17 men were normal BF%, and 19 women and 4 men were high BF%. Of the older group, 19 women and 4 men were normal BF%, and 29 women and 15 men were high BF%. Volunteers were screened for general health and habitual physical activity via questionnaire prior to participation. Exclusion criteria included history of lower limb muscle/tendon/joint disorders that affected mobility or the ability to exert maximum plantar-/dorsiflexor force; any chronic inflammatory condition; immunosuppressant medication; pregnancy; history of lower-limb resistance training in the six months prior to the start of the study; participation in \>2 hourly sessions of structured physical activity a week; cognitive impediments.

Experimental design
-------------------

Participants visited the laboratory on three separate occasions within 14 days. During the first session, participants provided a fasted 10 ml venous blood sample, from which serum levels of 12 inflammatory cytokines were quantified, and a sub-sample of participants were instructed how to use a 3-day food and drink diary, which was used to analyse habitual dietary fat intake. All 142 participants were subsequently familiarised to the muscle function assessments, which consisted of isometric and isokinetic plantar flexor (PF) and dorsiflexor (DF) maximum voluntary contractions (MVCs), and ramp isometric PF contractions to measure gastrocnemius medialis (GM) muscle architecture (fascicle length, *L*~f~, and pennation angle, *θ*~p~). On the second visit, participants completed a full body dual-energy X-ray absorptiometry (DXA) scan in the fasted state to assess total body composition. GM muscle volume was then determined from axial ultrasound scans and muscle length in 127 (men, *n*=32; women, *n*=95) participants. On the third and final visit, participants repeated the muscle function assessments, and the highest MVC scores from either the familiarisation or third laboratory session were used for subsequent analysis. The muscle function and morphology measurements were all performed on the dominant limb. Joint torque, joint angle, electromyographic (EMG) activity and electrical stimulation signals were interfaced with an analogue-to-digital converter (Biopac Systems Inc, Santa Barbara, USA), sampled at 2,000 Hz and displayed on the screen of an iMac computer (Apple, Cupertino, USA) using AcqKnowledge software (Biopac Systems).

Body composition
----------------

Participants a whole body DXA scan (Discovery W, Hologic Inc., Bedford, USA) between 08:00 and 09:00 after a 12 h fast. Total body fat mass, lean mass, and body fat percentage (BF%), were calculated using Hologic APEX software (version 3.3).

Dietary fat intake
------------------

Habitual dietary fat profiles of a subsample of 61 subjects were assessed using a three-day food diary recorded over two weekdays (Thursday and Friday) and one weekend day (Saturday). Subjects recorded their eating and drinking habits in as much detail as possible, e.g., time of meal, weight of food/ingredients in grams and volume of drink in mL, commercial brand names of food/ingredients and drink, any leftovers and cooking preparation methods. Dietary analysis was conducted using Nutritics software (version 1.8, Nutritics Ltd., Co. Dublin, Ireland). From the food analysis, dietary fat (absolute values and normalised to body mass) for each subject was calculated as an average over the three-day period.

Neuromuscular measurements
--------------------------

### PF and DF MVCs

Participants sat on the chair of an isokinetic dynamometer (Cybex Norm, Cybex International, New York, USA) with a hip angle of 85° (180° corresponding to the supine position) and were firmly strapped at the hip, distal thigh and chest with inextensible straps to minimise extraneous movement. The dominant leg was fully extended and the foot was securely fastened to the dynamometer footplate with the lateral malleolus aligned with the axis of rotation. Participants performed 2--3 isometric PF and DF MVCs (iMVCs) for 2--3 s (alternating between PF and DF every 60 s) at each of the following ankle joint positions: −5° (DF), 0° (neutral position, foot 90° to tibia) and 10° (PF). DF iMVCs were performed to obtain maximum DF EMG, in order to calculate antagonist co-activation during PF iMVC (see below). Participants also performed three consecutive isokinetic PF MVCs (ikMVCs) at 60° s^−1^ from −5° to 10°.

### Antagonist muscle co-activation

After appropriate skin preparation, two bipolar Ag-AgCl surface EMG electrodes (Neuroline, Medicotest, Rugmarken, Denmark) were placed 20 mm apart along the sagittal axis over the proximal third of the tibialis anterior (TA) muscle belly (SENIAM), with a reference electrode positioned over the lateral tibial condyle. The EMG signal was pre-amplified (× 2,000) and filtered using high- and low-pass filters set at 10 and 500 Hz, respectively (plus notch filter at 50 Hz). The root mean square (RMS) of the EMG signal was calculated over 1 s around the peak torque during each PF and DF MVC at all three joint angles. Thus, antagonist torque output during PF iMVC was calculated by dividing TA EMG RMS during PF iMVC by TA EMG RMS during DF iMVC, and multiplying DF iMVC torque by this ratio. The sum of the antagonist torque and PF iMVC torque was used to calculate maximum Achilles tendon force and GM muscle specific force (see below).

### Voluntary muscle activation

The level of voluntary muscle activation was measured using the interpolated twitch technique (ITT) during the PF iMVCs with the joint set at 0°. Electrical muscle stimulation was administered percutaneously to the PF muscle group via two 5 × 10 cm self-adhesive electrodes (American Imex, Irvine, USA) placed distal to the popliteal crease (cathode) and the myotendinous junction of the soleus (anode). A supramaximal doublet (two twitch stimuli of 0.2 ms pulse width, administered at 100 Hz) was manually applied at rest (control doublet) 3 s before iMVC, and once during iMVC. The level of voluntary muscle activation was given by:

where *t* is the force of the superimposed doublet and *T* is the force of the control doublet. This percentage was used to calculate the maximum isometric torque able to be produced by the PF group (PF max torque) at each joint angle, as shown below:

### Achilles tendon moment arm

The tendon excursion method using B-mode ultrasonography (AU5 Harmonic, Esaote Biomedica, Genoa, Italy), as described previously,^[@bib38],\ [@bib39]^ was used to determine the Achilles tendon moment arm. Participants were secured to the dynamometer chair and foot-plate (ankle set at 0°), as described above. A 2 mm wide, 2 cm long strip of surgical tape (3M, Neuss, Germany) was attached to the skin, transversely over the GM myotendinous junction (MTJ). The 4 cm wide, 7.5 MHz linear array ultrasound probe was then positioned sagitally over the tape to record the passive movement of the GM MTJ while the ankle was rotated between the angles of −5° and 10° at a constant velocity of 1° s^−1^. The ultrasound scan (including three continuous PF and DF rotations) was synchronised with the joint angle signal via a square wave signal generator. The displacement of the MTJ between 10° and −5° was measured with image analysis software (ImageJ, National Institutes of Health, Bethesda, USA) and the Achilles tendon moment arm at 0° was calculated as the MTJ displacement divided by change in the joint angle during a complete rotation (15°).

### Achilles tendon force (F~*t*~)

*F*~t~ was calculated by dividing PF max torque by the Achilles tendon moment arm.

### Muscle volume

GM muscle volume (*V*~m~) was measured with B-mode ultrasonography (AU5 Harmonic), using previously described methods validated in the *vastus lateralis* muscle.^[@bib40]^ Participants lay relaxed in the prone position with the ankle angle set to 0°. The proximal end (0%) and 25, 50, 75 and 100% (distal end) of the GM muscle were located and marked on the skin. At 25, 50 and 75% muscle length, the lateral and medial boundaries were located and marked on the skin. The ultrasound probe was subsequently orientated in the axial plane, aligned perpendicular to the GM muscle, and moved along each pre-marked axial line at 25, 50 and 75% muscle length. Individual frames were exported and used to re-construct the anatomical cross-sectional areas (ACSAs) of the GM at 25, 50 and 75% muscle length using image-editing software (Photoshop, Adobe Systems Europe Ltd, Maidenhead, UK). Each of the three ACSAs was then measured using ImageJ. GM muscle volume (*V*~m~) was then calculated by treating the muscle as a series of truncated cones.^[@bib40]^ Each of the four truncated cones was calculated using the following equation, where *d* is the distance between two ACSAs (*a* and *b*):

The sum of the four cones provided the total GM *V*~m~.

### GM muscle architecture and PCSA

With the ankle joint set at 0°, the ultrasound probe was placed sagitally over the centre of the GM muscle, in line with the direction of the fascicles. The participant performed a ramped PF iMVC, gradually increasing torque over the course of 6 s. The frame depicting the GM muscle architecture at peak PF iMVC was exported and fascicle pennation angle (*θ*~p~, the angle at which the fascicles insert into the lower aponeurosis) and length (*L*~f~) were measured using ImageJ. The mean of the three *θ*~p~ and *L*~f~ measurements were subsequently used to calculate GM muscle fascicle force (GM *F*~f~) and GM physiological cross-sectional area (PCSA), respectively (see below).

### GM muscle fascicle force (F~f~)

Based on the relative proportion of GM muscle volume to total PF muscle volume,^[@bib41]^ the contribution of GM muscle to *F*~t~ was assumed to be 20.3%. Therefore, GM *F*~f~ was calculated by dividing *F*~t~ by the cosine of GM *θ*~p~, as shown below:

### GM muscle PCSA and specific force

GM PCSA at iMVC was calculated as GM *V*~m~/*L*~f~. Subsequently, dividing GM *F*~f~ by GM PCSA provided GM muscle specific force.

Serum inflammatory cytokine concentration
-----------------------------------------

Participants provided a 10 ml fasted blood sample between 08:00 and 09:00, having performed no strenuous exercise for 48 h. Blood was collected in to an anticoagulant free vacutainer (BD Vacutainer Systems, Plymouth, UK) and serum was prepared and stored in 2 ml aliquots at −20 °C until subsequent analysis. Seventy-eight serum samples were randomly selected for cytokine analysis from a list of participant numbers with BMI and age as a guide for selection (the investigator was blinded to all other participant information). Consequently, 39 young and 39 older (*n*=48 BF%\<40; *n*=31 BF%⩾40) participants were selected for analysis. Serum concentrations of eight inflammatory cytokines (pro-inflammatory: IL-1β, IL-6, TNF-α, G-CSF; anti-inflammatory: IL-10, TGF-β1, TGF-β2, TGF-β3) and four chemokines (IL-8, MCP-1, MIP-1α, MIP-1β) were measured using multiplex luminometry. A 3-plex panel was used to measure TGF-β1, β2 and β3 concentrations (R&D Systems Europe Ltd, Abingdon, UK) and a Bio-Plex Pro Human Inflammation Panel Assay (Bio-Rad laboratories Ltd., Hemel Hempstead, UK) was used to measure the remaining nine cytokines, following the manufacturer\'s instructions. Samples were analysed using a Bio-Plex 200 system (Bio-Rad laboratories Ltd., Hemel Hempstead, UK).

Statistical analyses
--------------------

IBM SPSS statistics (version 23, SPSS Inc., Chicago, IL) was used for all analyses. Two-way ANOVAs with Scheffe post hoc tests were used to determine the main effects of age, adiposity, and interaction for all of the study parameters. A Freidman\'s ANOVA was used to compare between days differences in dietary fat content. Bivariate Pearson correlations were used to ascertain relationships between the serum concentration of individual inflammatory cytokines, and fat/muscle characteristics. Partial correlations (controlling for total body fat mass) were performed to determine the relationships between inflammatory cytokine concentration and muscle variables independently of fat mass. Partial correlations (controlling for age) were performed to determine the relationships between inflammatory cytokine concentration and muscle variables independently of age. Statistical significance was accepted when *P*⩽0.05. Data are presented as means±s.d. unless otherwise stated.

Results
=======

Anthropometry, body composition
-------------------------------

The younger individuals were taller (*P*\<0.05), had a greater body mass (*P*\<0.05) and greater lean mass (*P*\<0.05) than the older participants ([Table 1](#tbl1){ref-type="table"}). There was no effect of adiposity on total body lean mass (*P*\>0.05), although there was a tendency for the young high BF% group to have greater lean mass than the older high BF% group (ANOVA, age × adiposity, *P*=0.055). Young high BF% also presented with higher body mass, BMI and fat mass than the other three groups (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}). As expected, adiposity was positively associated with body mass, BMI and BF% (all, *P*\<0.05) ([Table 1](#tbl1){ref-type="table"}).

Maximum strength
----------------

### PF isometric and isokinetic MVC ankle joint torque

Regarding absolute iMVC, there was a main effect of age: young individuals produced higher PF iMVC compared to older persons (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}). There was also a main effect of adiposity, with high adipose persons being stronger than those of normal adiposity (*P*=0.007). However, there was no age × adiposity interaction (*P*=0.289; [Table 1](#tbl1){ref-type="table"}). Regarding absolute PF ikMVC, there was a main effect of age: young individuals produced higher ikMVC compared to older persons (*P*\<0.001). There was no main effect of adiposity (*P*=0.128; [Table 1](#tbl1){ref-type="table"}) and no age × adiposity interaction (*P*=0.396; [Table 1](#tbl1){ref-type="table"}).

### Maximum Achilles tendon force (F~t~)

There was a main effect of age, i.e., young individuals produced greater *F*~t~ compared to older persons (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}), and a main effect of adiposity, with high adipose persons producing greater force than normal adipose individuals (*P*=0.020), but there was no age × adiposity interaction (*P*=0.472; [Table 1](#tbl1){ref-type="table"}).

### Maximum GM fascicle force (F~f~)

There was a main effect of age, i.e., younger individuals produced greater *F*~f~ than older persons (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}), and there was a main effect of adiposity (*P*=0.002), with high adipose persons producing more force than normal adipose individuals. However, there was no age × adiposity interaction (*P*=0.237; [Table 1](#tbl1){ref-type="table"}).

### Maximum strength normalised to muscle size

After normalising iMVC and ikMVC to GM *V*~m~, there were main effects for age on iMVC/*V*~m~, i.e., older persons had lower iMVC/*V*~m~ and ikMVC/*V*~m~ than young individuals (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}), and there were main effects for adiposity (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}), with normal demonstrating greater muscle quality than high adipose persons. There were also age × adiposity interactions (*P*\<0.05), i.e., young individuals with normal BF% had greater muscle quality compared to all other groups (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}). Regarding GM muscle specific force, there were no main effects of age or adiposity, or any interaction between age and adiposity (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}).

### Voluntary muscle activation capacity

There were significant main effects for both age (*P*=0.001; [Table 1](#tbl1){ref-type="table"}) and adiposity (*P*=0.011; [Table 1](#tbl1){ref-type="table"}), demonstrating that young individuals had higher muscle activation capacity than older persons, and that persons with high BF% (regardless of age) had lower activation capacity than persons with normal BF%. There was no age × adiposity interaction (*P*=0.185; [Table 1](#tbl1){ref-type="table"}).

Muscle morphology
-----------------

### GM muscle volume and PCSA

There were main effects for age on GM *V*~m~ and PCSA: young persons had larger *V*~m~ and PCSA than older individuals (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}); and main effects for adiposity: persons with high BF% had larger *V*~m~ and PCSA than persons with normal BF% (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}). There were also age × adiposity interactions: young persons with high BF% had larger muscle volume and PCSA than all other groups (*P*\<0.001; [Table 1](#tbl1){ref-type="table"}).

### GM muscle architecture

There were main effects for both age (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}) and adiposity (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}), i.e., young persons had larger GM *θ*~p~ than older individuals, while persons with high BF% had larger *θ*~p~ than persons with normal BF% (*P*\<0.05; [Table 1](#tbl1){ref-type="table"}). However, there was no age × adiposity interaction with GM *θ*~p~ (*P*\>0.05). Further, there were no effects of age (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}) or adiposity (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}), and there was no age × adiposity interaction (*P*\>0.05; [Table 1](#tbl1){ref-type="table"}) with GM fascicle length.

Serum inflammatory cytokine concentration
-----------------------------------------

### Associations with age and/or adiposity

Serum IL-6 concentration showed a significant main effect for age (*P*=0.004), with older participants having higher serum concentrations than young individuals ([Table 2](#tbl2){ref-type="table"}). There was no main effect of adiposity, and no interaction between age and adiposity (*P*\>0.05). There was also an age × adiposity interaction (*P*=0.016) regarding serum MCP-1, with older individuals of high adiposity having higher levels than older normal adipose persons. Finally, there was a main effect of adiposity concerning TGF-β2 (*P*=0.008), with high adipose persons having a greater serum concentration of this cytokine than those of normal adiposity ([Table 2](#tbl2){ref-type="table"}).

### Correlations with muscle and fat phenotypes in young and older persons combined

The positive and inverse relationships between serum IL-6, IL-1β, MCP-1, MIP-1α and MIP-1β concentrations and adiposity and muscle properties in young and older individuals combined are shown in [Table 3](#tbl3){ref-type="table"}.

### Correlations with muscle and fat phenotypes in young persons only

The inverse correlation between serum IL-6 concentration and voluntary activation and, after controlling for BF%, the partial correlation between serum IL-6 and voluntary activation are shown in [Table 4](#tbl4){ref-type="table"}. Likewise, the inverse correlations between serum IL-1β and BMI, iMVC, ikMVC, fat mass, lean mass, GM PCSA, GM *θ*~p~, (*r*⩾−0.325; *P*⩽0.049), and between serum MIP-1α and BF% (*r*=−0.343; *P*=0.035) and fat mass (*r*=−0.323; *P*=0.048) are displayed in [Table 4](#tbl4){ref-type="table"}. The positive correlations between serum MIP-1β and iMVC, GM *V*~m~, GM *L*~f~, *F*~t~, GM PCSA, (*r*⩾0.339; *P*⩽0.040) and inverse correlation with ikMVC/*V*~m~ (*r*=−0.402; *P*=0.028) are also shown in [Table 4](#tbl4){ref-type="table"}.

### Correlations with muscle and fat phenotypes in older persons only

Serum MCP1 correlated positively with BMI, BF% and fat mass (*r*⩾0.378; *P*⩽0.028; [Table 4](#tbl4){ref-type="table"}). Serum TNF-α correlated positively with iMVC, ikMVC, lean mass, GM *θ*~p~, *F*~t~, GM *F*~f~, (*r*⩾0.458; *P*⩽0.048; [Table 4](#tbl4){ref-type="table"}). After controlling for total body fat mass, TNF-α correlated with iMVC, lean mass, GM *θ*~p~, GM *F*~f~, (*r*⩾0.510; *P*⩽0.044; [Table 4](#tbl4){ref-type="table"}). Serum IL-8 correlated positively with voluntary muscle activation (*r*=0.382; *P*=0.016; [Table 4](#tbl4){ref-type="table"}), and controlling for fat mass strengthened this correlation (*r*=0.414; *P*=0.010; [Table 4](#tbl4){ref-type="table"}).

### Correlations with muscle and fat phenotypes in persons of normal and high adiposity

The positive and inverse relationships between serum IL-6, IL-1β, IL-8, TNF-α, MCP-1, MIP-1β, and G-CSF concentrations and adiposity and muscle properties in persons of normal and high adiposity are shown in [Table 5](#tbl5){ref-type="table"}. Most notably, IL-6 correlated inversely with on muscle quality in both normal and high adipose individuals (*r*⩾−0.367; *P*⩽0.042; [Table 5](#tbl5){ref-type="table"}), MIP-1β correlated with numerous measures of maximum muscle force and size in normal adipose persons (*r*⩾0.332; *P*⩽0.039; [Table 5](#tbl5){ref-type="table"}), and IL-8 correlated inversely with measures of muscle strength and quality in high adipose individuals (*r*⩾−0.364; *P*⩽0.044; [Table 5](#tbl5){ref-type="table"}), but positively with muscle quality in persons of normal adiposity (*r*=0.604; *P*=0.038; [Table 5](#tbl5){ref-type="table"}).

Habitual dietary fat intake
---------------------------

A Friedman\'s ANOVA revealed no between days difference (*P*=0.448) between daily fat intake over the three-day dietary analysis period. For daily absolute fat intake, there was a main effect for age with young individuals consuming more fat than older persons (*P*=0.041; [Table 6](#tbl6){ref-type="table"}). There was no main effect for adiposity (*P*=0.088; [Table 6](#tbl6){ref-type="table"}) but there was an age × adiposity interaction, with young normal consuming more fat than all other groups (*P*\<0.05) but otherwise no other differences (*P*\>0.05). For daily fat intake normalised to body mass, there was no main effect for age (*P*\>0.05) but there was a main effect for adiposity (*P*\<0.001; [Table 6](#tbl6){ref-type="table"}), with normal consuming more fat than high. There was also an age × adiposity interaction (*P*=0.021; [Table 6](#tbl6){ref-type="table"}): young normal and old normal consumed per fat than both young high and old high. Concerning the daily amount of fat consumed as a percentage of total energy intake, there was no main effect of age (*P*=0.869) but there was a main effect for adiposity (*P*=0.043) and an age × adiposity interaction (*P*=0.025; [Table 6](#tbl6){ref-type="table"}), with normal young consuming a greater percentage of fat compared to high young (*P*=0.014). Finally, regarding the daily amount of fat consumed as a percentage of total macronutrient intake, there was no main effect of age (*P*=0.696) or adiposity (*P*=0.070), and no age × adiposity interaction (*P*=0.161; [Table 6](#tbl6){ref-type="table"}).

### Correlations between habitual dietary fat content and cytokines

In young persons only, serum IL-1β (*r*=0.976; *P*=0.010) and IL-8 (*r*=0.879; *P*=0.021) correlated with absolute (g/day) fat intake. In older persons only, TGF-β3 correlated with fat intake, both in absolute terms (*r*=0.567; *P*=0.022) and normalised to body mass (*r*=0.509; *P*=0.044). In young and older individuals combined, TGF-β3 correlated positively with daily fat intake, both in absolute terms (*r*=0.561; *P*=0.015) and normalised to body mass (*r*=0.512; *P*=0.030).

Discussion
==========

We aimed to determine whether circulating inflammatory cytokine levels could explain the different effects of obesity on skeletal muscle size, architecture and strength previously reported in young vs older adults. Our data suggest that, in young adults, serum IL-6 has a negative impact on neuromuscular activation, while IL-1β has a negative, and MIP-1β a positive, influence on muscle size, structure and strength ([Table 4](#tbl4){ref-type="table"}). In older adults, elevated IL-8 was positively associated with greater neuromuscular activation, while unexpectedly, TNF-α correlated positively with muscle mass, architecture and maximum strength ([Table 4](#tbl4){ref-type="table"}). In persons of normal adiposity, MIP-1β appears to play a very positive role in muscle size and strength, while IL-8 has a largely negative relationship with muscle quality (maximum strength normalised to either muscle size or body mass) in high adipose individuals ([Table 5](#tbl5){ref-type="table"}).

In line with previous research, we have shown that serum IL-6 concentration was higher in older vs young adults.^[@bib27],\ [@bib28]^ Furthermore, IL-6 correlated with BMI, total body fat mass and BF% in young and older individuals combined, which is in line with previous work.^[@bib32]^ Moreover, the inverse relationship between IL-6 and voluntary muscle activation was particularly interesting given the positive relationships between IL-6 and adiposity reported here ([Table 3](#tbl3){ref-type="table"}) and elsewhere,^[@bib12],\ [@bib14],\ [@bib15]^ and between IL-6 and ageing.^[@bib27],\ [@bib28]^ This inverse relationship (even after controlling for BF%) strongly suggests that IL-6 has a negative effect on the ability to voluntarily activate skeletal muscle. This may well be influenced by central inflammation, i.e., elevated levels of IL-6 and other pro-inflammatory cytokines in the hippocampus and hypothalamus (induced by a high fat diet^[@bib31]^), which lead to neuroinflammation.^[@bib29]^ This potentially reduces an individual\'s ability to activate their muscles voluntarily, thus impairing muscle size and function. Not only might this help explain the significantly lower muscle activation and absolute strength values in older vs younger individuals reported here and elsewhere,^[@bib6],\ [@bib20],\ [@bib21],\ [@bib30]^ but it might also explain the lower muscle activation capacity we found here in young and older persons with high vs normal BF%. Although we did not find a relationship between IL-6 and habitual dietary fat intake, we did observe positive relations between fat intake and other pro-inflammatory cytokines (IL-1β and IL-8).

IL-8 is a chemokine that acts as a neutrophil chemotactic factor^[@bib42]^ and is therefore pro-inflammatory. It has previously been associated with obesity,^[@bib43]^ which coincides with our finding of higher (though non-significant) serum IL-8 levels in older persons with high BF% compared to older lean and younger adults. Surprisingly, we found that serum IL-8 correlated positively with voluntary muscle activation in older adults. As IL-8 is known to induce angiogenesis,^[@bib42]^ enhance endothelial cell proliferation and have an anti-apoptotic effect,^[@bib44]^ it is possible that this chemokine provides a protective, or rescuing, effect against neuroinflammation in older adults.

Both TNF-α mRNA content and TNF-α production are elevated in adipose tissue of obese individuals,^[@bib12]^ while circulating TNF-α concentration also rises with obesity.^[@bib45]^ We found a non-significant trend for serum TNF-α to correlate inversely with iMVC, and a significant inverse correlation between serum IL-1β and muscle size and strength and adiposity in young adults. In contrast, TNF-α correlated positively with iMVC, ikMVC, lean mass, GM *θ*~p~, maximum tendon force and GM fascicle force in older adults, thus suggesting age-dependent effects of TNF-α on skeletal muscle characteristics. After controlling for fat mass, TNF-α remained positively correlated with older muscle size and strength. This indicates the effect of TNF-α was not due to fat mass *per se*, which is supported by TNF-α being produced almost exclusively by macrophages within adipose tissue, as opposed to the adipocytes themselves.^[@bib11]^ Skeletal muscle also produces TNF-α^[@bib46]^ and, although it has catabolic properties (thus possibly explaining the inverse correlation with iMVC in young adults), it has been shown to stimulate protein synthesis^[@bib47]^ and positively influence maximum strength^[@bib48]^ during the various phases of muscle remodelling. Furthermore, TNF-α induces IL-6 production in myoblasts^[@bib49]^ and IL-6, in combination with TNF-α, stimulates myoblast growth.^[@bib50]^ Therefore, it is feasible that the muscles of those older individuals with elevated serum TNF-α produced more IL-6, thus having a beneficial rather than deleterious effect on muscle size and strength.

In contrast to our TNF-α results, serum MIP-1β, correlated positively with muscle size, architecture and absolute strength in young adults, and with numerous measures of muscle size, structure and strength in persons of normal adiposity. MIP-1β is a chemoattractant for monocytes^[@bib51]^ and interacts with MIP-1α,^[@bib52]^ which correlated inversely with adiposity in our young participants. Thus, it appears that these chemokines have a positive effect on skeletal muscle properties in young but not in older muscle, and may therefore explain the previously reported lower muscle quality in older vs young adults.^[@bib21]^

Our study has highlighted novel relationships between numerous circulating cytokines and precise measures of neuromuscular properties in young and older individuals of varied adiposity. These relationships indicate potential mechanisms that may explain the lower muscle quality in obese vs normal weight individuals,^[@bib7]^ and in older vs younger persons,^[@bib21]^ seen here and elsewhere. However, we acknowledge certain limitations with our study; as cognitive function was not a focus of this study (although our selection criteria excluded cognitively challenged volunteers), it is not possible to make a direct comparison with those previous studies that associated high levels of IL-6 with cognitive decline^[@bib29]^). Furthermore, contrary to our hypothesis based on previous work,^[@bib31]^ our data did not exhibit any association between habitual dietary fat intake and circulating IL-6 (although we did observe positive correlations between fat intake and IL-β1 and IL-8 in young persons). Nevertheless, our reported inverse relationship between IL-6 and voluntary muscle activation in young individuals is as expected in a physiological system linking high IL-6 with poor neuronal integration. Future human studies should consider these parameters (cognition, IL-6 endocrine profile, and diet) longitudinally. We would also recommend that studies employing an animal model may wish to build on previous work,^[@bib31]^ by characterising neurodegeneration and muscle size and strength in young vs old animals fed with a high vs low fat diet. In older persons, we found that IL-8 correlated positively with voluntary activation but, to our knowledge, there is no evidence linking IL-8 with neurogenesis or repair following damage due to ageing. Future studies may wish to investigate this potential protective mechanism against neurodegeneration in older persons by measuring the effect of high vs low doses of IL-8 on damaged neurons *in vitro* and on neurological properties in an animal model *in vivo*. Finally, our somewhat surprising relationships between TNF-α and muscle size and strength in older persons only may be explained by TNF-α acting in a dose-response manner to reduce the rate of sarcopenia. Indeed in cell culture models, a concentration of this cytokine (as well as dependent on the order in which various cytokines are introduced in the culture dish), the effects of TNF-α can either induce hypertrophy or alternatively, muscle breakdown.^[@bib50],\ [@bib53]^

To conclude, our data suggest that obesity has a greater anabolic effect on young compared to older human muscle, but that it attenuates muscle quality more in young compared to older adults. The inverse relationship between serum IL-6 and voluntary muscle activation in young adults, and the chronically elevated levels of IL-6 and lower voluntary muscle activation levels in older adults, suggest that IL-6-induced neuroinflammation plays a role in reducing voluntary muscle strength. Interestingly, the unexpected positive relationship between IL-8 and voluntary muscle activation in older adults suggests this chemokine may be differentially impacting neuroinflammation and hence neuromuscular activation. The positive relationship between TNF-α and muscle mass and strength in older adults in the current cohort, whilst potentially supporting previous reports of TNF-α having a positive effect on skeletal muscle properties, is yet to be fully understood given the weight of the previous published evidence pertaining to the contrary (i.e., a deleterious muscle protein synthesis and/or stimulatory impact on the rate of protein degradation). Collectively, these age- and adiposity-dependent relationships provide evidence that circulating pro-inflammatory cytokines play different roles in neuromuscular remodelling according to the age and adiposity of the individual.
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###### Body composition and gastrocnemius medialis (GM) muscle strength (*n*=142), size and architecture (*n*=127) of the study participants according to age and body fat percentage (BF%)

  *Variable*                                *Young (*n=*75)*                                         *Older (*n=*67)*                                                                         
  ----------------------------- ----------------------------------------- ----------------------------------------------------------------------- ------------------------------------------- -----------------------------------------------------------------------
                                          *Normal BF% (*n=*52)*                                     *High BF% (*n=*23)*                                      *Normal BF% (*n=*23)*                                      *High BF% (*n=*44)*
  Age (yrs)                                    24.04±8.42                                               28.04±9.69                                  65.52±7.98^[a](#t1-fn3){ref-type="fn"}^                   66.02±7.29^[a](#t1-fn3){ref-type="fn"}^
  Height (m)                                    1.70±0.10                                                1.68±0.08                                  1.63±0.09^[a](#t1-fn3){ref-type="fn"}^                    1.65±0.06^[a](#t1-fn3){ref-type="fn"}^
  Body mass (kg)                               65.56±13.50                 94.93±14.13^[b](#t1-fn4){ref-type="fn"},[c](#t1-fn5){ref-type="fn"}^    62.23±14.13^[a](#t1-fn3){ref-type="fn"}^    79.65±14.64^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  BMI (m/kg^2^)                                22.75±3.87                   33.81±4.86^[b](#t1-fn4){ref-type="fn"},[c](#t1-fn5){ref-type="fn"}^     23.16±3.43^[a](#t1-fn3){ref-type="fn"}^     29.23±5.33^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  Body fat (%)                   27.59±6.92^[c](#t1-fn5){ref-type="fn"}^                  43.30±6.56^[b](#t1-fn4){ref-type="fn"}^                                 32.31±9.93                                  40.60±7.04^[b](#t1-fn4){ref-type="fn"}^
  Body fat mass (kg)                           17.70±6.42                   40.13±8.85^[b](#t1-fn4){ref-type="fn"},[c](#t1-fn5){ref-type="fn"}^     19.59±5.72^[a](#t1-fn3){ref-type="fn"}^     31.64±9.70^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  Body lean mass (kg)                          43.62±9.53                                 49.60±8.26^[b](#t1-fn4){ref-type="fn"}^                   38.89±9.67^[a](#t1-fn3){ref-type="fn"}^     43.26±8.14^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  iMVC PF torque (N·m)                        173.64±44.17                               200.75±42.92^[b](#t1-fn4){ref-type="fn"}^                 133.37±36.60^[a](#t1-fn3){ref-type="fn"}^   145.20±34.41^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  ikMVC PF torque (N·m)                        92.34±25.18                                             102.00±21.10                                60.51±20.83^[a](#t1-fn3){ref-type="fn"}^                  63.27±20.85^[a](#t1-fn3){ref-type="fn"}^
  VA (%)                                       95.29±5.51                                88.02±11.04^[b](#t1-fn4){ref-type="fn"}^                  86.58±14.15^[a](#t1-fn3){ref-type="fn"}^    84.28±12.05^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  *F*~t~ (N)                                    5245±1357                                 5949±1631^[b](#t1-fn4){ref-type="fn"}^                    4026±1079^[a](#t1-fn3){ref-type="fn"}^      4400±1055^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  GM *F*~f~ (N)                                 1221±334                                   1471±427^[b](#t1-fn4){ref-type="fn"}^                     930±274^[a](#t1-fn3){ref-type="fn"}^        1042±273^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  GM *V*~m~ (cm^3^)                           214.59±61.61                 310.75±59.37^[b](#t1-fn4){ref-type="fn"},[c](#t1-fn5){ref-type="fn"}^   203.66±43.24^[a](#t1-fn3){ref-type="fn"}^   217.11±49.19^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  GM *θ*~p~ (°)                                30.58±5.09                                 35.10±3.95^[b](#t1-fn4){ref-type="fn"}^                   27.71±4.73^[a](#t1-fn3){ref-type="fn"}^     30.36±4.60^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  GM *L*~f~ (cm)                                3.65±0.58                                                3.73±0.54                                                 3.94±0.78                                                 3.86±0.60
  GM PCSA (cm^2^)                              60.20±16.52                 85.86±18.00^[b](#t1-fn4){ref-type="fn"},[c](#t1-fn5){ref-type="fn"}^    52.50±13.23^[a](#t1-fn3){ref-type="fn"}^    57.14±13.93^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  iMVC/BM (N·m/kg)                              2.59±0.58                                 1.99±0.36^[b](#t1-fn4){ref-type="fn"}^                    2.10±0.41^[a](#t1-fn3){ref-type="fn"}^      1.71±0.34^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  ikMVC/BM (N·m/kg)                             1.43±0.28                                 1.09±0.25^[b](#t1-fn4){ref-type="fn"}^                    0.97±0.25^[a](#t1-fn3){ref-type="fn"}^      0.80±0.25^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  iMVC/*V*~m~ (N·m/cm^3^)        0.81±0.18^[c](#t1-fn5){ref-type="fn"}^                   0.65±0.14^[b](#t1-fn4){ref-type="fn"}^                                   0.66±0.14                                  0.68±0.15^[b](#t1-fn4){ref-type="fn"}^
  ikMVC/*V*~m~ (N·m/cm^3^)       0.43±0.12^[c](#t1-fn5){ref-type="fn"}^                   0.34±0.09^[b](#t1-fn4){ref-type="fn"}^                    0.30±0.10^[a](#t1-fn3){ref-type="fn"}^      0.30±0.08^[a](#t1-fn3){ref-type="fn"},[b](#t1-fn4){ref-type="fn"}^
  GM specific force (N/cm^2^)                  21.07±5.85                                               17.59±5.28                                                18.35±5.33                                                18.80±4.72

Abbreviations: BM, body mass; BMI, body mass index; *F*~t~, maximum Achilles tendon force; *GM F*~f~, gastrocnemius medialis fascicle force; ikMVC, isokinetic maximum voluntary contraction; iMVC, isometric maximum voluntary contraction; *L*~f~, muscle fascicle length; PCSA, physiological cross-sectional area; VA, voluntary muscle activation; *V*~m~, muscle volume; *θ*~p~, muscle fascicle pennation angle.

Values are mean±s.d.

Significant effect of age (*P*\<0.05).

Significant effect of BF% (*P*\<0.05).

Significant age × BF% interaction (*P*\<0.05).

###### The serum concentration of pro-inflammatory cytokines in 12--78 study participants (the number of participants varies according to the ability to measure certain cytokines in the serum)

  *Cytokine(pg/mL)*      *Young (*n=*39)*               *Older (*n=*39)*                                                     
  ------------------- ----------------------- ------------------------------------- ---------------------------------------- ----------------------------------------
                       *Normal BF% (*n=*28)*           *High BF% (*n=*11)*                   *Normal BF% (*n=*11)*                     *High BF% (*n=*28)*
  IL-1β                      1.03±0.17                      0.69±0.17                              0.70±0.18                                0.72±0.12
  IL-6                       0.93±0.16                      1.28±0.19                1.78±0.26^[a](#t2-fn3){ref-type="fn"}^   2.09±0.22^[a](#t2-fn3){ref-type="fn"}^
  IL-8                       9.53±0.93                      8.59±1.43                              8.35±1.00                                11.80±1.07
  IL-10                      3.51±0.64                      2.95±0.59                              2.29±0.29                                4.20±0.86
  TNF-α                      3.90±0.78                      3.12±1.21                              3.69±1.32                                4.84±1.01
  MCP-1                       208±44                         114±29                                  85±22                     329±73^[b](#t2-fn4){ref-type="fn"}^
  MIP-1α                     3.81±0.65                      2.03±0.37                              2.45±0.59                                1.94±0.23
  MIP-1β                      101±23                         101±29                                  68±12                                    126±31
  G-CSF                     28.50±5.70                     13.41±4.78                             21.69±15.45                              45.12±12.34
  TGF-β1                    32,261±7539                   29,193±9,041                            12,625±2,003                             38,862±6,596
  TGF-β2                      341±33           413±92^[c](#t2-fn5){ref-type="fn"}^                   200±21                    407±43^[c](#t2-fn5){ref-type="fn"}^
  TGF-β3                      273±84                         184±63                                  122±37                                   334±69
  IL-10: IL-6                3.55±0.79                      5.17±1.32                              1.61±0.31                                3.76±1.01

Abbreviations: G-CSF, granulocyte-colony stimulating factor; IL-1β, interleukin-1β MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α MIP-1β, macrophage inflammatory protein-1β TGF-β1, transforming growth factor-β1; TNF-α, tumour necrosis factor α.

Values are mean±s.e.

Significant effect of age (*P*\<0.05).

Significant age × BF% interaction (*P*\<0.05).

Significant effect of BF% (*P*\<0.05).

###### Correlations between inflammatory cytokines and measures of adiposity and muscle characteristics (with and without controlling for FM) in young and older persons combined

  *Variable*                           *Cytokine*                                                                                                                     
  --------------------------- ---------------------------- --------------------------- --------------------------- ---------------------- --------------------------- ----------------------
  BMI (kg m^-2^)                  *r*=0.326; *P*=0.008                                  ***r*=−0.318; *P*=0.005**   *r*=0.251; *P*=0.047  ***r*=−0.209; *P*=0.074**              
  BF%                             *r*=0.357; *P*=0.003                                  ***r*=−0.332; *P*=0.003**   *r*=0.297; *P*=0.018  ***r*=−0.378; *P*=0.001**              
  FM (kg)                         *r*=0.380; *P*=0.002                                  ***r*=−0.335; *P*=0.003**   *r*=0.341; *P*=0.006  ***r*=−0.306; *P*=0.008**              
  VA (%)                       ***r*=−0.370; *P*=0.002**    ***r*=−0.311; *P*=0.022**                                                     *r*=0.234; *P*=0.046                   
  ikMVC (N·m)                  ***r*=−0.279; *P*=0.024**    ***r*=−0.317; *P*=0.020**                                                                                            
  ikMVC/*V*~m~ (N·m cm^-3^)    ***r*=−0.355; *P*=0.008**    ***r*=−0.260; *P*=0.057**     *r*=0.258; *P*=0.038                            *r*=0.238; *P*=0.068                   
  ikMVC/BM (N·mkg^-1^)         ***r*=−0.470; *P*\<0.001**   ***r*=−0.344; *P*=0.011**                                                     *r*=0.267; *P*=0.022                   
  iMVC/BM (N·mkg^-1^)          ***r*=−0.455; *P*\<0.001**   ***r*=−0.307; *P*=0.024**     *r*=0.271; *P*=0.018                            *r*=0.258; *P*=0.027                   
  iMVC/*V*~m~ (N·m cm^-3^)     ***r*=−0.257; *P*=0.058)**                                                                                                                        
  GM *V*~m~ (cm^3^)                                                                                                                                                    *r*=0.267; *P*=0.032
  GM PCSA (cm^2^)                                                                                                                                                      *r*=0.216; *P*=0.084

Abbreviations: BF, body fat; BM, body mass; BMI, body mass index; FM, fat mass; GM *V*~m~, gastrocnemius medialis muscle volume; ikMVC, isokinetic maximum voluntary contraction; IL, interleukun; iMVC, isometric maximum voluntary contraction; PCSA, physiological cross-sectional area; VA, voluntary muscle activation.

Inverse correlations are indicated in bold.

###### Correlations between inflammatory cytokines and measures of adiposity and muscle characteristics (with and without controlling for BF% or FM) according to age (young vs older persons)

  *Variable*                         *Cytokine*                                                                                                                                                                                                                      
  -------------------------- --------------------------- --------------------------- --------------------------- --------------------------- --------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------------
  BMI (kg m^-2^)                                                                      ***r*=−0.330; *P*=0.043**                                                           *r=*0.378; *P*=0.028                                                                                  
  BF%                                                                                                             ***r*=−0.343; *P*=0.001**                               *r=*0.428; *P*=0.011                                                                                  
  FM (kg)                                                                             ***r*=−0.357; *P*=0.028**   ***r*=−0.323; *P*=0.048**                               *r=*0.514; *P*=0.002                                                                                  
  LM (kg)                                                                             ***r*=−0.360; *P*=0.026**                                                                                  *r=*0.645; *P*=0.003   *r=*0.655; *P*=0.003                                    
  VA (%)                      ***r*=−0.376; *P*=0.022**   ***r*=−0.362; *P*=0.050**                                                                                                                                                            *r=*0.382; *P*=0.016   *r=*0.414; *P*=0.010
  iMVC (N·m)                                                                          ***r*=−0.333; *P*=0.044**                                 *r=*0.356; *P*=0.030                             *r=*0.588; *P*=0.008   *r=*0.589; *P*=0.010                                    
  ikMVC (N·m)                                                                         ***r*=−0.325; *P*=0.049**                                                                                  *r=*0.483; *P*=0.036                                                           
  ikMVC/*V*~m~ (N·mcm^-3^)                                                                                                                    ***r*=−0.402; *P*=0.028**                                                                                                         
  *F*~t~ (N)                                                                                                                                    *r=*0.339; *P*=0.040                             *r=*0.492; *P*=0.032                                                           
  GM *F*~f~ (N)                                                                                                                                                                                  *r=*0.534; *P*=0.019   *r=*0.535; *P*=0.022                                    
  GM *V*~m~ (cm^3^)                                                                                                                             *r=*0.566; *P*=0.001                                                                                                            
  GM *θ*~p~ (°)                                                                       ***r*=−0.414; *P*=0.013**                                                                                  *r=*0.458; *P*=0.048   *r=*0.482; *P*=0.043                                    
  GM *L*~f~ (mm)                                                                                                                                *r=*0.393; *P*=0.019                                                                                                            
  GM PCSA (cm^2^)                                                                     ***r*=−0.409; *P*=0.025**                                 *r=*0.386; *P*=0.035                                                                                                            

Abbreviations: BF, body fat; BMI, body mass index; *F*~t~, maximum Achilles tendon force; FM, fat mass; GM *F*~f~, maximum gastrocnemius medialis muscle fascicle force; GM *V*~m~, gastrocnemius medialis muscle volume; ikMVC, isokinetic maximum voluntary contraction; IL, interleukun; iMVC, isometric maximum voluntary contraction; *L*~f~, fascicle length; LM, lean mass; PCSA, physiological cross-sectional area; TNF, tumor necrosis factor; VA, voluntary muscle activation; *θ*~p~, fascicle pennation angle.

Inverse correlations are indicated in bold.

###### Correlations between inflammatory cytokines and measures of adiposity and muscle characteristics (with and without controlling for age) according to adiposity (normal vs high)

  *Variable*                          *Cytokine*                                                                                                                                                                                                                                                                                                                     
  -------------------------- ----------------------------- --------------------------- ---------------------- ---------------------- ---------------------- ----------------------- ----------------------- --------------------------- --------------------------- --------------------------- ---------------------- ---------------------- ---------------------- ----------------------
  BMI (kgm^-2^)                                                                                                                                              *r*=0.386; *P*=0.015                                                                                                                                                                                               
  BF%                                                       ***r*=−0.391; *P*=0.014**                                                                                                                                                                                                                                                                                           
  FM (kg)                                                   ***r*=−0.417; *P*=0.008**                                                                        *r*=0.332; *P*=0.039                                                                                                                *r*=0.507; *P*=0.010                                                           
  iMVC (N·m)                                                                                                                                                 *r*=0.363; *P*=0.025                                                        ***r*=−0.396; *P*=0.014**                                                                                                              
  ikMVC (N·m)                                                                                                                                                *r*=0.457; *P*=0.004    *r*=0.793; *P*=0.022                                                                                                                                                                       
  *F*~t~ (N)                                                                                                                                                 *r*=0.393; *P*=0.015                                                        ***r*=−0.412; *P*=0.010**   ***r*=−0.364; *P*=0.044**                                                                                  
  GM *F*~f~ (N)                                                                                                                                              *r*=0.387; *P*=0.016                                                        ***r*=−0.401; *P*=0.013**                                                                                                              
  Sp. force (Ncm^-2^)                                                                                                                                                                                                                                                ***r*=−0.432; *P*=0.015**                          *r*=0.594; *P*=0.009   *r*=0.848; *P*=0.033             
  iMVC/*V*~m~ (N·mcm^-3^)                                                                                                             *r*=0.517; *P*=0.040                                                                                                           ***r*=−0.456; *P*=0.010**                                                                        *r*=0.901; *P*=0.014
  ikMVC/*V*~m~ (N·mcm^-3^)                                                              *r*=0.643; *P*=0.024   *r*=0.604; *P*=0.038                                                                                                                                                                                                                                             
  iMVC/BM (N·mkg^-1^)                                                                                                                                                                                        ***r*=−0.378; *P*=0.028**                                                                                                                                          
  ikMVC/BM (N·mkg^-1^)        ***r*= − 0.367; *P*=0.042**                                                                                                                                                                                                                                                                                                                       
  GM *V*~m~ (cm^3^)                                                                                                                                          *r*=0.695; *P*\<0.001   *r*=0.868; *P*\<0.001                                                                                                                                                                      
  GM PCSA (cm^2^)                                                                                                                                            *r*=0.550; *P*=0.001    *r*=0.739; *P*=0.006                                                                                                                                                                       

Abbreviations: BF, body fat; BM, body mass; BMI, body mass index; FM, fat mass; *F*~t~, maximum Achilles tendon force; G-CSF, granulocyte-colony stimulating factor; GM *F*~f~, maximum gastrocnemius medialis muscle fascicle force; GM *V*~m~, gastrocnemius medialis muscle volume; ikMVC, isokinetic maximum voluntary contraction; IL, interleukin; iMVC, isometric maximum voluntary contraction; *L*~f~, fascicle length; LM, lean mass; PCSA, physiological cross-sectional area; Sp. force, gastrocnemius muscle specific force; VA, voluntary muscle activation; *θ*~p~, fascicle pennation angle.

Inverse correlations are indicated in bold.

###### Habitual dietary fat intake measured using a 3-d food and drink diary (Thurs--Sat)

  *Measure of fat intake*                                    *Young (*n=*15)*                           *Older (*n=*46)*                                                         
  --------------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------ ----------------------------------------------------------------------
                                                          *Normal BF% (*n=*10)*                        *High BF% (*n=*5)*                       *Normal BF% (*n=*14)*                                     *High BF% (*n=*32)*
  Absolute fat intake (g/d)                      98.45±31.18^[a](#t6-fn2){ref-type="fn"}^   68.76±20.80^[b](#t6-fn3){ref-type="fn"}^   66.40±16.20^[c](#t6-fn4){ref-type="fn"}^   72.93±18.79^[b](#t6-fn3){ref-type="fn"},[c](#t6-fn4){ref-type="fn"}^
  Fat intake normalised to body mass (g/kg/d)     1.31±0.47^[a](#t6-fn2){ref-type="fn"}^     0.70±0.19^[b](#t6-fn3){ref-type="fn"}^     1.11±0.26^[a](#t6-fn2){ref-type="fn"}^                   0.93±0.23^[b](#t6-fn3){ref-type="fn"}^
  \% fat of total energy intake (%)              35.90±5.71^[a](#t6-fn2){ref-type="fn"}^    28.40±7.20^[b](#t6-fn3){ref-type="fn"}^                   32.23±4.53                                32.64±5.31^[b](#t6-fn3){ref-type="fn"}^
  \% fat of total macronutrient intake (%)                      20.90±3.45                                 17.20±4.15                                 18.85±3.24                                               18.85±3.61

Values are mean±s.d.

Significant age × BF% interaction (*P*\<0.05).

Significant effect of BF% (*P*\<0.05).

Significant effect of age (*P*\<0.05).
